



March 1, 2017

## **Akebia to Host Conference Call on March 6th to Discuss Full-Year 2016 Financial Results and Corporate Highlights**

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that the Company will host a conference call on Monday, March 6, 2017 at 4:30 PM ET to discuss the financial results for the year ended December 31, 2016, and recent corporate highlights.

### **Conference Call and Webcast**

Date: March 6, 2017

Time 4:30 PM ET

Telephone Domestic Callers: dial (877) 458-0977  
Access: International Callers: dial (484) 653-6724  
Please reference the Akebia conference call  
Passcode: 77605143

Online Go to the Investor Relations section of the Akebia website and follow instructions for accessing the live  
Access: webcast. Please connect to the website at least 15 minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary. An archived presentation will be available for 90 days.

Telephone A telephone replay will be available for 5 days following the call.  
Replay: Replay for domestic Callers: dial (855) 859-2056  
Replay for international Callers: dial (404) 537-3406  
Passcode: 77605143

### **About Akebia Therapeutics**

Akebia Therapeutics, Inc. is a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Akebia's lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. Akebia's global Phase 3 program for vadadustat, which includes the PRO<sub>2</sub>TECT studies for non-dialysis patients with anemia associated with chronic kidney disease and the INNO<sub>2</sub>VATE studies for dialysis-dependent patients, is currently ongoing. For more information, please visit our website at [www.akebia.com](http://www.akebia.com).

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20170301005439/en/>

#### **Akebia Therapeutics, Inc.**

Theresa McNeely, 617-844-6113

SVP, Corporate Communications and Investor Relations

[Tmcneely@akebia.com](mailto:Tmcneely@akebia.com)

Source: Akebia Therapeutics, Inc.

News Provided by Acquire Media